About: Bhavneesh Sharma

Bhavneesh Sharma

Top 20 Ranking (28.2% Avg Return) --TipRanks

Bhavneesh Sharma is a contributing analyst at FATRADER where he covers biotechnology and pharmaceuticals. A market expert with a medical degree and MBA, he is ranked among the top 15 financial bloggers and top 100 overall financial experts (including Wall Street analysts) on TipRanks.

Bhavneesh holds a Master of Business Administration degree with specialization in finance and financial markets from New York University's Stern School of Business, ranked among top 3 finance MBAs in the country. He has authored several highly-cited peer reviewed scientific publications and was awarded the Young Investigator Award at the international level twice by the American Chest Foundation and American College of Chest Physicians.

Bhavneesh's main strategy is event-driven, covering companies with near-term catalysts like data releases, PDUFA, etc. He capitalizes on his years of clinical and research experience with financial expertise (DCF modeling, etc.) to find profitable event-driven investments in the volatile U.S. biotech/pharma sector.

Successful picks have included Juno Therapeutics (picked after clinical hold), Alnylam Pharmaceuticals (picked after clinical hold), Dynavax (doubled after CRL), Neurocrine Biosciences, Sage Therapeutics, Sarepta Therapeutics (picked after negative Adcom), Zogenix, Editas medicine, Teva Pharmaceuticals (picked after the drop below $15), Tobira Therapeutics (picked after trial failure, etc.). Tobira and Juno went on to be acquired.

He is also a registered financial adviser and widely followed contributor to Seeking Alpha and SumZero.

Story Archive


Homology Medicines: Novel Homologous Non-nuclease Gene Editing Technology

Homology Medicines (FIXX) is a gene editing company that has a novel AAV-HSCs technology which was licensed from the City of Hope Med Center.
by Bhavneesh Sharma - 3 days ago


Atara Bio: Another Attractive Name in Allogeneic CAR-T Space

The company’s key developmental program is focused on developing off-the-shelf allogeneic T cell therapies against certain malignancies.
by Bhavneesh Sharma - 4 days ago


CRISPR Therapeutics (CRSP): Novel gene editing approach in CAR-T therapy

CRISPR Therapeutics's approach to developing allogeneic CAR-T cells involves multiple steps to overcome these challenges presented by solid tumors.
by Bhavneesh Sharma - 2 weeks ago


Why Moderna (MRNA) Could Revolutionize the Way We Treat Cancers

In this second article in a 2-part series, my focus will be describing the oncology pipeline of Moderna Therapeutics, which I consider as one of the large future revenue drivers.
by Bhavneesh Sharma - 3 weeks ago


Moderna Therapeutics: Potential to Disrupt a $200B+ Market

Part 1 of a 2 part series breaking down the opportunity in Moderna (MRNA) and how it could join the large-cap club in biotech companies.
by Bhavneesh Sharma - 1 month ago


A Techie Shows the Biotech World How Cancer is Treated

The Parker Institute fund launched 3 years ago by Napster founder and the first Facebook President Sean Parker, highlighted preliminary results this weekend at the American Association for Cancer Research conference that have the possibility of changing the way cancer immunotherapy trials will be designed in the future.
by Bhavneesh Sharma - 1 month ago


T2 Biosystems: Breakthrough technology revolutionizing sepsis management, from the labs at Harvard/MIT

I am bullish on the commercial potential of T2 Biosystems (TTOO)'s diagnostic tests for sepsis containing bacteria, as well as for certain resistant infections like CRE and for Lyme's disease.
by Bhavneesh Sharma - 1 month ago

Breaking News Analysis: Apple Watch's Results in Screening for Atrial Fibrillation

Apple (AAPL) announced results of a large study that used Apple Watch to screen for atrial fibrillation, a common arrhythmia.
by Bhavneesh Sharma - 2 months ago

HOT OFF THE PRESS: Insights from the annual Cowen Healthcare conference for Monday

Notes on Wave Sciences (WVE), Moderna Therapeutics (MRNA), Insmed (INSM), Magenta Therapeutics (MGTA), and Axovant Gene Therapies (AXGT).
by Bhavneesh Sharma - 2 months ago


Invitae: The 'Amazon of Genetics' and a $22 billion market opportunity

Invitae (NYSE: NVTA) is a leading genetics company which is aiming to bring foster, affordable and high-quality genetic testing to millions of people for various health conditions.
by Bhavneesh Sharma - 2 months ago

Sign Up Now - Free 15-Day Trial! Go! Fatty!